Table 1 Recent patent applications in DNA diagnostics
Patent number | Description | Assignee | Inventor | Priority application date | Publication date |
|---|---|---|---|---|---|
WO 2008127199, EP 2146740 | A method of preventing, inhibiting, arresting orreversing tumorigenesis in a cell, comprisingmodulating the amount or the activity of a Rabbinding protein. | Agency for Science, Technology and Research (Singapore) | Lim B, Miller LD, Zhang J | 4/13/2007 | 10/23/2008, 1/27/2010 |
US 20090325813 | A method of determining the level of target oligo-nucleotide suspected of being present in a sample for diagnosing, e.g., cancer, by measuring hybridization of the target and reference oligonucleotide to a test and calibration microarray and comparing the results. | Curry BU, Wang H | Curry BU, Wang H | 6/26/2008 | 12/31/2009 |
WO 2009147519 | A method of determining delivery rates and/or efficiency of a small interfering RNA (siRNA), microRNA (miRNA) or related molecule to/in target organs or cells, comprising measuring levels, in exosomes or vesicles of target organs or cells of siRNA and/or miRNA. | National Center for Research Sciences (Paris) | Gibbings D, Voinnet O | 6/6/2008 | 12/10/2009 |
WO 2009143624 | A method of determining the acute allograft rejection status of a subject by determining the nucleic acid expression profile of nucleic acid markers or proteomic expression profile of proteomic markers in a biological sample from the subject. | University of British Columbia (Vancouver, BC, Canada) | Balshaw R, Cohen Freue G, Gunther O, Keown P, McManus B, McMaster R, Meredith A, Mui A, Ng R, Scherer A | 5/30/2008 | 12/3/2009 |
WO 2009100029 | A diagnostic method aiding in the detection ofdisease or other medical condition, comprisingisolating a microvesicle fraction from a biologicalsample and detecting the presence or absence of abiomarker within the microvesicle fraction. | General Hospital Corp. (Boston) | Breakefield XO, Brown D, Miranda KC, Russo LM, Skog J | 2/1/2008 | 8/13/2009 |
WO 2009036513 | Identifying an epigenetic and genetic profile in a subject associated with a mental health condition, comprising detecting DNA methylation of the serotonin transporter (5HTT) promoter region and/or the level of expression of the 5HTT gene. | Murdoch Childrens Research Institute (Parkville, Victoria, Australia) | Craig JM, Olsson CA, Saffery R | 9/21/2007 | 3/26/2009 |
WO 2009033185 | A method of identifying druggable targets comprising obtaining a cell or organism with an RNA interference (RNAi) pathway, infecting the cell or organism with a virus, and assaying for a change in expression of the microRNAs in the cell or organism. | University of Massachusetts (Boston) | Kowalik TF, Stadler BM | 9/6/2007 | 3/12/2009 |
WO 2008113773 | A nucleic acid molecule comprising a 7SL small-RNA– derived sequence comprising at least the binding domain to srp9 and srp14 proteins of the 7SL ribonucleocomplex, a sequence identical or complementary to a target sequence and a pol III type III promoter; useful for diagnosing an age-related pathology, e.g., Alzheimer's disease. | Biorigen (Genoa, Italy) | Pagano A | 3/16/2007 | 9/25/2008 |
WO 2008103135 | A new isolated microRNA (miRNA) polynucleotide, useful for diagnosing and treating a colorectal cancerin a subject, and for screening for test agents which that affect miRNA generation. | Johns Hopkins University (Baltimore, MD, USA) | Cummins J, Kinzler KW, Velculescu V, Vogelstein B | 2/16/2007 | 8/28/2008 |
WO 2008097926 | A new linear double-stranded DNA templatecomprising an open reading frame encoding atherapeutic, prophylactic or diagnostic polypeptide or nucleic acid molecule; useful for in vitro transcription of RNA and treating or inhibiting disorders. | Yale University (New Haven, CT, USA) | Bahceci E, Komarovskaya ME, Rabinovich PM, Weissman SM | 2/2/2007 | 8/14/2008 |
